Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Paradigm Biopharmaceuticals Ltd. successfully raised $16 million through a strategic placement to support its global Phase 3 clinical trials for osteoarthritis treatment, starting in Australia and expanding to the U.S. This capital injection will also fund other strategic initiatives, enhancing shareholder value with options that could yield an additional $63 million. The company’s pro forma cash balance post-raise is expected to be $26.9 million, providing financial stability into the second half of 2025.
For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.
